Clinical Trials Sponsored by EmCyte Corporation

Total 6473 results

Incyte Corporation

Recruiting

A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa (STOP-HS LTE)

Hidradenitis Suppurativa (HS)

United States, Austria, Belgium, Canada, Germany, Poland, Spain, Australia, Denmark, France, United Kingdom, Japan, Bulgaria, Netherlands, Czechia, Greece, Italy
Incyte Corporation

Recruiting

A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

NonSegmental Vitiligo

Germany, United States, Italy, Poland, Canada, France, Bulgaria, Hungary, United Kingdom
Incyte Corporation

Recruiting

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms (LIMBER)

Myeloproliferative Neoplasms

Spain, Japan, France, Italy, Germany, Australia, United Kingdom, Denmark, Canada
Incyte Corporation

Recruiting

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease (THRIVE)

cGVHD

United States
Incyte Corporation

Recruiting

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

Advanced Solid Tumor

Brazil, Georgia, Greece, Turkey, Mexico, Romania, South Africa, Hungary, New Zealand, China
Incyte Corporation

Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Solid Tumors | Metastatic Solid Tumors

United States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
Incyte Corporation

Recruiting

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (MORPHEUS)

Atopic Dermatitis

United States
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
Incyte Corporation

Terminated

Study of INCB086550 in Select Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Non Small Cell Lung Cancer | Urothelial Cancer

Korea, Republic of, Bulgaria, Hungary, Taiwan, Ukraine
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Vitiligo

NonSegmental Vitiligo

United States, Canada
Incyte Corporation

Active, not recruiting

Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis

Atopic Dermatitis (AD)

Canada, United States, Poland
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.

Healthy Participants

United States
Incyte Corporation

Completed

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

Kidney Diseases | Renal Insufficiency

United States, Germany
Incyte Corporation

Completed

Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

United States, Canada
Incyte Corporation

Available

Expanded Access Program for Axatilimab in Chronic Graft Versus Host Disease (GVHD)

Chronic Graft Vs. Host Disease
Incyte Corporation

Active, not recruiting

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

Follicular Lymphoma | Marginal Zone Lymphoma

Finland, United States, Spain, Korea, Republic of, Canada, Israel, Turkey, United Kingdom, Netherlands, Greece, Italy, France, Taiwan, Germany, Belgium, Japan, Czechia, Switzerland, Ireland, Poland, Ukraine, Australia, Denmark, Hungary, Swede... and more
Incyte Corporation

Completed

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis

Kidney Diseases | Renal Insufficiency

United States, Germany
Incyte Corporation

Terminated

An Umbrella Study to Determine the Safety and Efficacy of Various Monotherapy or Combination Therapies in Neoadjuvant Urothelial Carcinoma (Optimus)

Urothelial Carcinoma

United States, France, Italy
Incyte Corporation

Completed

A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo

Vitiligo

United States, Canada
Incyte Corporation

Terminated

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Chronic Graft-versus-host Disease

United States, Spain, France, Canada, Israel, United Kingdom, Germany, Italy, Denmark, Sweden, Finland, Belgium, Poland, Greece, Austria, Switzerland
Incyte Corporation

Completed

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen Sclerosus

Lichen Sclerosus

United States, Canada
Incyte Corporation

Active, not recruiting

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)

Glioblastoma | Adult-type Diffuse Gliomas

United States, Spain, Italy, United Kingdom, Germany, Japan, France, Netherlands, Denmark
Incyte Corporation

Active, not recruiting

Study of INCA 0186 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Gastrointestinal (GI) Malignancies

United States, Netherlands, Spain, United Kingdom, Belgium, Austria
Incyte Corporation

Active, not recruiting

A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (topMIND)

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States, Spain, France, Italy, Belgium, Germany, Austria
Incyte Corporation

Active, not recruiting

Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

Squamous Cell Carcinoma of the Anal Canal

United States, Italy, Spain, United Kingdom, Australia, France, Germany, Sweden, Japan, Norway, Belgium, Denmark, Puerto Rico
Incyte Corporation

Active, not recruiting

A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies

Advanced Solid Tumors

United States, Sweden, Netherlands, Norway, Denmark
Incyte Corporation

Completed

A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

Ovarian Cancer | Endometrial Cancer | Solid Tumors | Biliary Tract Cancer (BTC) | Colorectal Cancer (CRC) | Gastroesophageal Cancer (GC)

United Kingdom, United States, Belgium
Incyte Corporation

Completed

A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors

Solid Tumors

United States, Italy, United Kingdom, France, Belgium
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation

Bronchiolitis Obliterans Syndrome

United States, Belgium, Canada
Incyte Corporation

Active, not recruiting

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)

Warm Autoimmune Hemolytic Anemia (wAIHA)

Spain, United States, Austria, Belgium, Canada, France, Germany, Israel, Italy, Japan, Netherlands, Poland, United Kingdom
Incyte Corporation

Completed

The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis (SCRATCH-AD)

Atopic Dermatitis

Canada
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
Incyte Corporation

Completed

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

Atopic Dermatitis

United States
Incyte Corporation

Completed

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

B-Cell Malignancies

United States
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
Incyte Corporation

Completed

A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)

Lymphoma

Japan
Incyte Corporation

Completed

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

Metastatic Melanoma | Unresectable Melanoma | Metastatic Urothelial Cancer | Metastatic Non-small Cell Lung Cancer | Locally Advanced Renal Cell Carcinoma | Locally Advanced Urothelial Cancer | Metastatic Clear-Cell Renal Cell Carcinoma

France, Spain, United States, Italy, Austria, Romania, Poland, Hungary
Incyte Corporation

Completed

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

Head and Neck Cancer | Gastric Cancer | Lung Cancer | Metastatic Cancer | Mesothelioma | Bladder Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer)

Italy, Spain, United States, Netherlands
Incyte Corporation

Terminated

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Acute Graft-versus-host Disease

United States, Spain, France, Italy, United Kingdom, Germany
Incyte Corporation

Approved for marketing

Expanded Access of Ruxolitinib Cream to Treat a Single Patient With cGVHD

Graft-versus-host Disease (GVHD)
Incyte Corporation

Completed

A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Hidradenitis Suppurativa

Canada, Denmark, Germany
Incyte Corporation

Completed

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Non-segmental Vitiligo

United States, Canada, Italy, France, Germany, Spain, Poland, Bulgaria, Netherlands
Incyte Corporation

Completed

INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)

B-cell Lymphoma

United States, Spain, Italy
Incyte Corporation

Completed

A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]-INCB086550

Healthy Volunteers

United Kingdom
Incyte Corporation

Completed

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States, Netherlands, Austria
Incyte Corporation

Completed

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Melanoma | Breast Cancer | Head and Neck Cancer | Pancreatic Cancer | Lung Cancer | Endometrial Cancer | Solid Tumors | Renal Cell Carcinoma (RCC) | Colorectal Cancer (CRC) | UC (Urothelial Cancer) | MMR-deficient Tumors

United States
Incyte Corporation

Completed

A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis

Psoriasis

United States
Incyte Corporation

Terminated

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

COVID-19

United States, Russian Federation
Incyte Corporation

Completed

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Breast Cancer | Multiple Myeloma | Gastric Cancer | Lung Cancer | Solid Tumor | Cholangiocarcinoma | Endometrial Cancer | Urothelial Cancer | Myeloproliferative Neoplasms | UC | MPN

United States, Denmark
Incyte Corporation

No longer available

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

COVID-19

Clinical Trials Sponsored by EmCyte Corporation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations